Company Milestones
COMPANY MILESTONES
2012
Accidental discovery of core technology during emission reduction research
2014
First medical application developed to help founder's father.
2014-2017
Experimental R&D phase — 100+ people impacted across various health conditions
2017
Optimum Bio Innovations Limited (OBIL) formally established as an R&D company focusing on optimising biology.
2017-2019
Utilising advanced analytics, analysed feedback and medical diagnostics from beta users.
Developed first OBST System for launch in 2020.
2020
Plans to soft-launch put on hold - forced to restructure due to Covid.
Registered U.S. Entity in Delaware (DE) for U.S. FDA liaison and future U.S. Expansion.
Received NZ Government (Callaghan Innovation) $400K NZD R&D loan.
2021
FDA Class I Medical Device (510(k)-exempt) registration achieved via DE.
2021
NZ Medsafe registration achieved.
2022
OptiRTP Limited established as subsidiary - IP for human health tech application transferred from OBIL.
2022
Obtained rare global approval from Apple Inc. for medical app status (OBST).
2023
Soft-launched OptiRTP in New Zealand targeting high performance athletes with injuries.
2024
Expanded NZ influencer base: now Endorsed by Olympians, Paralympians, National Team Captains & Coaches.
2025
U.S. market entry begins
Engaged AI across product, onboarding, and global infrastructure — accelerating the growth plan, reducing operating costs, and overcoming prior scalability barriers
November 2025
Presented at inaugural NZSCA-SPRINZ Strength & Conditioning Practitioners Day.
December 2025
Co-therapy discussions commence with NZ pharmaceutical companies.
Read more.
2026: (Planned)
VA Augusta Phantom Limb Pain clinical study begins (June)
Autonomous Android platform launch.
2027 (Planned)
Clinical study completion and reimbursement pathway expansion
Japan market entry preparation
2028 (Planned)
Japan market expansion.
